Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth... Custirsen is also being investigated in the treatment of primary brain tumors.
- Mechanism
- Curator reviewed
CC-8490 acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms.
Preliminary results in studies regarding the mechanism of action in brain cancer suggest that C-8490 surpresses nuclear factor (NF)-KB with its target genes IEX-3, SOD2, IL6, and IL8.
- Primary indication
- Investigated for use/treatment in brain cancer and breast cancer.Curator reviewed
- Code names
- CC-8490 · OGX-011
Resolves to
What you can answer from here — as of September 12, 2026
Which drugs share a target with Custirsen, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account